Chinese Academy of Medical Sciences
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Fruquintinib-Capecitabine Combination Shows Promise as Maintenance Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
• Phase 1/2 study data presented at the 2025 AACR Annual Meeting revealed promising efficacy of fruquintinib plus capecitabine as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer patients.
• At a median follow-up of 5.7 months, the disease control rate reached 90.9% with median progression-free survival not yet reached, and two patients experienced disease control lasting more than 430 days.
• The recommended phase 2 dose was established at 5 mg daily of fruquintinib on days 1-14 of each 3-week cycle, with a manageable safety profile showing 87.5% of patients experiencing treatment-related adverse effects, mostly mild to moderate.
Qilu Pharmaceutical's QLS32015 Shows Promise in Relapsed/Refractory Multiple Myeloma
• Qilu Pharmaceutical's QLS32015, a GPRC5D/CD3-targeting bispecific antibody, demonstrates encouraging anti-tumor activity in RRMM patients.
• Phase Ia trial results reveal a 76.9% objective response rate (ORR) in heavily pre-treated relapsed/refractory multiple myeloma (RRMM) patients.
• The bispecific antibody was well-tolerated, with cytokine release syndrome (CRS) being the most common treatment-related adverse event (TRAE).
• QLS32015 represents a novel approach, bridging T cells to GPRC5D-expressing tumor cells, offering a potential new treatment option for RRMM.
Innovent's Taletrectinib (DOVBLERON®) Receives Expanded Approval in China for ROS1-Positive NSCLC
• China's NMPA has approved Innovent's taletrectinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
• The approval was based on positive outcomes from the Phase II TRUST-I trial, which showed high and durable overall responses.
• In TKI-naïve patients, taletrectinib achieved a confirmed objective response rate of 91% and intracranial cORR of 88%.
• Taletrectinib is now approved for both first-line and previously treated ROS1-positive NSCLC patients in China.
Flonoltinib and Selinexor Combinations Show Promise in Myelofibrosis Treatment
• Flonoltinib demonstrated significant spleen and symptom response in myelofibrosis patients, suggesting it may be a new treatment option.
• A phase 2 trial showed selinexor combined with ruxolitinib led to spleen length reduction and symptom alleviation in myelofibrosis patients previously treated with ruxolitinib.
• Navitoclax combined with ruxolitinib showed durable responses and potential disease modification in relapsed/refractory myelofibrosis, improving spleen volume and symptoms.
• These studies highlight potential new strategies for myelofibrosis treatment, addressing unmet needs in patients with limited options.
Neoadjuvant Immunochemotherapy Plus Chemoradiation Improves Outcomes in Esophageal Cancer
• A phase II trial showed that chemoradiation followed by immunochemotherapy and surgery improved outcomes in patients with unresectable, locally advanced esophageal squamous cell carcinoma.
• The combination therapy led to a high rate of tumor resectability (66.7%) and pathologic complete response (65.0%) in treated patients.
• The 1-year progression-free survival rate was 79.4%, and the 1-year overall survival rate was 89.6% with the novel treatment approach.
• R0 resection was associated with significantly longer progression-free and overall survival compared to patients who did not undergo surgery.
Novel Immunochemotherapy Regimen Shows Promise in Unresectable Esophageal Cancer
• A Phase II trial demonstrates the safety and efficacy of chemoradiotherapy followed by tislelizumab-based immunochemotherapy in patients with unresectable esophageal squamous cell carcinoma.
• The study achieved a 66.7% resectability rate, with 95.2% of resected patients achieving R0 resection, indicating no residual tumor after surgery.
• Patients who underwent surgery had significantly longer progression-free survival and overall survival compared to those who did not.
• The combination therapy showed manageable safety profiles, with common adverse events including radiation esophagitis and pneumonitis.
Immunotherapy Plus Chemoradiation Improves Outcomes in Esophageal Cancer
• A phase II trial shows that adding immunotherapy to chemoradiation can improve outcomes for esophageal cancer patients.
• The triple combination of radiation, chemotherapy, and immunotherapy made tumors more amenable to surgery.
• Patients who underwent surgery after the triple therapy experienced significantly longer survival rates.
• A phase III trial (SCIENCE) showed that adding sintilimab to neoadjuvant chemoradiotherapy improved pathological complete response rates.
Equecabtagene Autoleucel Shows High Efficacy in Relapsed/Refractory Multiple Myeloma
• Equecabtagene Autoleucel demonstrated a 96% overall response rate in patients with relapsed/refractory multiple myeloma (R/RMM) who had received at least three prior therapies.
• The stringent complete response/complete response rate was 74.3%, with 95% of patients achieving minimal residual disease (MRD) negativity.
• The fully human anti-BCMA CAR-T therapy showed a favorable safety profile, with most cytokine release syndrome (CRS) cases being grade 1 or 2.
• A 12-month progression-free survival rate of 78.8% was observed, and 50% of patients had detectable vector copy number (VCN) at 12 months post-infusion.
ARANOTE Trial: Darolutamide Plus ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
• The ARANOTE trial demonstrated that darolutamide plus androgen deprivation therapy (ADT) significantly improves radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
• Darolutamide-treated patients experienced a 46% reduction in the risk of radiographic progression or death compared to those receiving ADT plus placebo, with consistent benefits across subgroups.
• The combination therapy also delayed time to castration-resistant prostate cancer and pain progression, while showing a favorable safety profile with lower rates of fatigue.
• These findings suggest darolutamide plus ADT could become a new standard of care for mHSPC, offering an alternative to chemotherapy-based regimens.
HS-20093 Shows Promise in Pretreated Extensive-Stage Small Cell Lung Cancer
• HS-20093, a B7-H3-targeted antibody-drug conjugate, demonstrated encouraging antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC).
• In the ARTEMIS-001 trial, HS-20093 achieved an overall response rate (ORR) of 61.3% at 8 mg/kg and 50.0% at 10 mg/kg in ES-SCLC patients.
• The disease control rate (DCR) was high in both cohorts, with 80.6% for the 8.0-mg/kg group and 95.5% for the 10.0-mg/kg group, indicating effective disease stabilization.
• The safety profile of HS-20093 was manageable, with hematologic adverse events being the most common, and the 8.0-mg/kg dose showing a better safety profile.
GnRH-a Plus Letrozole or LNG-IUD Compared to Progesterone for Atypical Endometrial Hyperplasia
• A clinical trial is underway comparing GnRH-a plus letrozole or LNG-IUD to traditional progesterone treatment for atypical endometrial hyperplasia (AEH).
• The study aims to assess the complete response rates of the combination therapies versus progesterone after 24 weeks of treatment.
• Secondary endpoints include pregnancy rates, recurrence rates, and safety profiles, offering a comprehensive evaluation of treatment efficacy.
• The trial incorporates rigorous data management and monitoring to ensure data quality and patient safety throughout the study.
Long-term efficacy and safety of iptacopan in PNH with anaemia
The article discusses the long-term efficacy and safety of iptacopan, a treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with anaemia, as presented by Prof. Antonio Risitano from the University of Naples, Italy.
© Copyright 2025. All Rights Reserved by MedPath